Wednesday, April 28, 2021
Here are pearls and takeaways from the session:
- Careful review of medical history/medications, physical examination and available radiology images is critical to accurately determining a patient’s future risk of osteoporotic fracture.
- Choice of therapy for a specific patient should be predicated on degree of fracture risk, with consideration of an anabolic agent as initial therapy in patients at very high risk of fracture.
- Consider the feasibility of a bisphosphonate drug holiday based on a patient’s BMD and risk of major osteoporotic fracture.
- Denosumab must not be discontinued without initiation of anti-resorptive therapy because of risk of BMD loss and vertebral fracture.
Duke Medicine Learning, Education, and Discussion Series (LEADS) takes place each Tuesday at 12 p.m. Learn more and see schedule of upcoming sessions.